Brain

Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005

– A-005 is a potential first-in-class, CNS penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – –…

1 month ago

Route 92 Medical Announces FDA 510(k) Clearance for FreeClimb 54 Reperfusion System

FreeClimb 54 reperfusion system Route 92 Medical's new FreeClimb 54 reperfusion system, part of a growing portfolio of neurovascular devices…

1 month ago

Shape Therapeutics to Showcase RNA Editing in the Brain and Validation of their Stable AAV Producer Cell Line at ASGCT 2024

SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader at the convergence of AI and RNA editing to…

1 month ago

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434…

1 month ago

Hyperfine, Inc. to Announce First Quarter 2024 Financial Results on May 13, 2024

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared…

1 month ago

IRLAB publishes Annual Report for 2023

GOTHENBURG, SWEDEN / ACCESSWIRE / April 29, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for…

1 month ago

Cerevance to Participate at Upcoming Investor Conferences

BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system…

1 month ago

Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™

The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for…

1 month ago

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim,…

1 month ago

ClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory

Key Accessory to the ClearPoint Prism® Neuro Laser Therapy Will Enable Operating Room Placement of Laser Fibers The ClearPoint Prism®…

1 month ago